Articles On Prescient Therapeutics (ASX:PTX)

Summary Prescient Therapeutics has appointed Professor H. Miles Prince to its Scientific Advisory Board. Professor Prince holds significant experience in several other areas of cancer therapies and drug development. He has pioneered t...

Summary Last 12 months have been fruitful for Prescient Therapeutics despite the challenges and uncertainties amid the COVID-19. The Company achieved its objectives for targeted as well as cell therapies during the period. A truly tra...

Summary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100. It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treat...

Summary Prescient ended the September 2020 quarter with a cash balance of almost A$18.6 million following the successful capital raising in August 2020. During the quarter, two assets of PTX were selected for priority antiviral COVID-19...

Summary Supported by an international leadership team with extensive expertise in cancer therapy, Prescient has developed a robust product pipeline, comprising personalised cancer treatments. Prescient’s drug pipeline comprises CAR-T an...

Prescient Therapeutics (ASX:PTX) has announced that it has received commitments to raise over $7 million before costs by way of a share placement to professional and sophisticated investors.

On 26 August 2020, Prescient Therapeutics Limited (ASX:PTX) announced that it has received firm commitments to raise A$7,046,084 (before costs) by way of a share placement of 128,110,611 fully paid ordinary shares to professional as well as...

Special Report: Prescient Therapeutics has boosted its cash balance to $20.3m, leaving it well funded to research targeted personalised CAR-T cancer treatments following a successful $13.5m capital raising. Prescient Therapeutics (ASX:PTX)...

Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The clinical stage oncology company today announced it has received firm commitments from professiona...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing direct...

ShareCafePrescient Therapeutics – ShareCafe Hidden Gems Webinar Presentation   Presenter – Steven Yatomi-Clarke – CEO & MD – Prescient is focused on developing novel, personalised therapies against a range of cancers. Prescient’s unive...

ShareCafeHidden Gems Webinar Recap – JHL, PTX, LNU   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Jayex Healthcare (ASX:JHL), Prescient Therapeut...

Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre, ‘Peter Mac’, a leader in new clinical treatments for cancer to develop CAR-T cell therapy technologies. The res...

Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing a collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) in Melbourne. The collaboration is expecte...

Summary After demonstrating the safety at a dose of 1,000 mg/m2, Phase 1b study of PTX-100 will proceed to the increased dose of 2,000 mg/m2. Two patients from the first 500 mg/m2 cohort had reported with stable disease or better at the...

Special Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its personalised treatments for cancer and COVID-19 and has launched a capital raising for up to $6.5m via a Share Purchase Plan (SPP). The cash ra...

Australia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed globally renowned cancer and Chimeric Antigen Receptor-T (CAR-T) expert, Professor Phillip Darcy of Peter MacCallum Cancer Centre, to its Sci...

Summary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose level of 35 mg/m2 PTX-200. Phase 1b study of PTX-200 at a dose of 25 mg/m2 demonstrated no dose-limiting toxicities and therapy was better to...

Prescient Therapeutics (ASX:PTX), The ASX-listed biotechnology player developing targeted and personalised medicines for challenging cancers, announced a Share Purchase Plan (SPP) to raise nearly A$6.5 million. The Company intends to use th...

Melbourne-based Prescient Therapeutics (ASX:PTX), a biotechnology company developing targeted and personalised medicines for cancer, has launched a $6.5 million capital raise.

Summary In June 2020 quarter, Prescient added new assets in its belt with the most significant milestone of a next-generation immunotherapy platform ‘OmniCAR’. Prescient onboarded former Juno Executive Dr Allen Ebens, having a vast ...

Clinical stage oncology company Prescient Therapeutics Limited (ASX:PTX) notified that two of its assets had been selected as Group 1 priority candidates for a COVID-19 antiviral testing program by Doherty Institute in Melbourne. Both asset...

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected as group one priority candidates for a COVID-19 antiviral testing program in Melbourne, Victoria. This is unexpected news to...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Prescient Therapeutics Limited (ASX:PTX) is a clinical-stage oncology company developing personalised medicine approaches to cancer, including cellular as well as targeted therapies. The targeted therapies include two drug candidates, PTX-2...

Well-known for developing breakthrough targeted and personalised medicines approaches to treat cancer, Prescient Therapeutics Limited (ASX:PTX) has been gaining attention on the back of its recent achievements. Building on this momentum, on...

The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products.

A quick wrap of the key winners and losers on Monday, June 1. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS CODE COMPANY PRICE...

Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licenses related to its universal immune receptor technology platform, currently in the pre-clinical development stage. In...

Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licences related to its universal immune receptor technology platform, currently in the pre-clinical development stage. In...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

ASX-listed Australia based clinical-stage oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in the development of new drugs that demonstrate significant promise as potential innovative therapies for the treatment of challe...

Clinical trials are being shuttered in increasing numbers in Australia because of the challenges posed by COVID-19; however, one clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) continues to march ahead. The Company...

Prescient Therapeutics (ASX:PTX) says the Phase 1b study of PTX-100 will proceed to the next dose level following successful completion of the first cohort of patients and demonstrating acceptable safety.

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has confirmed a phase 1b basket study of its cancer drug PTX-100 will proceed to the next dose level following successful completion on the first cohort of patients and achie...

Clinical trials are being shuttered in increasing numbers in Australia because of the risks posed by COVID-19, but two companies this morning say theirs are moving ahead at speed. Prescient Therapeutics (ASX:PTX) says its phase 1b study of...

Australian based clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX), recently reported operating highlights and financial outcomes for the March quarter 2020. The Company is engaged in the development of new drugs tha...

The Coronavirus has become a health threat across the globe and as per World Health Organization (WHO) until now this pandemic has resulted in over 72,744 deaths and infected more than 1,282,931 worldwide in just a few months (8 April 2020,...

1 in 6 deaths is due to cancer As per World Health Organization, Cancer is the 2nd major cause of death globally, and is responsible for an ~9.6 million deaths in 2018. Worldwide, about one in six deaths is owing to cancer. Demand for eff...

Prescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front...

Prescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

It’s fair to assume PainChek (ASX:PCK) shareholders are a happy bunch with a 12-month share price rise of 413 per cent. The rise of the pain-detection app company began in late April thanks to a $5m investment from the Morrison government....

Oncology company Prescient Therapeutics (ASX: PTX) has unveiled news of a high response rate to its PTX-200 leading drug candidate from a Phase 2 breast cancer trial. The news comes less than 2 weeks since Prescient announced positive inter...

Prescient Therapeutics (PTX) has reported a high response rate from its Phase 2a clinical trial for breast cancer All of the evaluable patients responded to the PTX-200 drug, with the disease completely eradicated in some patients All bu...

Clinical stage oncology company engaged in developing personalised medicine approaches including targeted and cellular therapies to beat cancer, Prescient Therapeutics (ASX: PTX) has been gaining industry limelight for its advancing clinica...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Oncology specialist company Prescient Therapeutics (ASX: PTX) has announced positive interim data from a Phase 1b safety study of its lead drug PTX-200 in women with recurrent or persistent platinum-resistant ovarian cancer. Conducted at th...